Diets rich in saturated fats may contribute to the loss of pancreatic b-cells in type 2 diabetes. JunB, a member of the activating protein 1 (AP-1) transcription factor family, promotes b-cell survival and mediates part of the beneficial effects of GLP-1 agonists. In this study we interrogated the molecular mechanisms involved in JunB-mediated b-cell protection from lipotoxicity. The saturated fatty acid palmitate decreased JunB expression, and this loss may contribute to b-cell apoptosis, as overexpression of JunB protected cells from lipotoxicity. Array analysis of JunB-deficient b-cells identified a gene expression signature of a downregulated endoplasmic reticulum (ER) stress response and inhibited AKT signaling. JunB stimulates XBP1 expression via the transcription factor c/EBPd during ER stress, and forced expression of XBP1s rescued the viability of JunB-deficient cells, constituting an important antiapoptotic mechanism. JunB silencing inhibited AKT activation and activated the proapoptotic Bcl-2 protein BAD via its dephosphorylation. BAD knockdown reversed lipotoxic b-cell death potentiated by JunB siRNA. Interestingly, XBP1s links JunB and AKT signaling as XBP1 knockdown also reduced AKT phosphorylation. GLP-1 agonists induced cAMP-dependent AKT phosphorylation leading to b-cell protection against palmitate-induced apoptosis. JunB and XBP1 knockdown or IRE1 inhibition decreased AKT activation by cAMP, leading to b-cell apoptosis. In conclusion, JunB modulates the b-cell ER stress response and AKT signaling via the induction of XBP1s. The activation of the JunB gene network and the crosstalk between the ER stress and AKT pathway constitute a crucial defense mechanism by which GLP-1 agonists protect against lipotoxic b-cell death. These findings elucidate novel b-cell-protective signal transduction in type 2 diabetes.
The prevalence of type 2 diabetes (T2D) has doubled in the past 30 years and has reached 360 million affected individuals worldwide. 1 In nondiabetic individuals, insulin resistance is compensated by increased insulin secretion by the pancreatic b-cells. Hyperglycemia develops in individuals who lack this compensatory response. This implies that b-cell dysfunction is an essential step in the pathogenesis of T2D. 2, 3 In autopsy studies, a decreased b-cell number of B40% is observed in T2D patients as compared with nondiabetic controls, 4 demonstrating that b-cell loss may also contribute to insulin deficiency.
The mechanisms leading to b-cell dysfunction and death are not well understood. Environmental factors such as diets rich in saturated fats and a sedentary lifestyle combined to an unfavorable genetic background increase T2D risk. 5 Lipid infusion in individuals who are genetically predisposed to T2D induces hepatic insulin resistance and impairs b-cell function. 6 Individuals with high fasting levels of plasma free fatty acids (FFAs) have an elevated risk of developing T2D. 7 Prolonged exposure to FFAs in vitro, particularly saturated FFAs such as palmitate, reduces insulin release and induces b-cell apoptosis. 8 Several studies have suggested that endoplasmic reticulum (ER) stress is a putative mediator of FFA-induced b-cell dysfunction and death in T2D. [9] [10] [11] [12] ER stress is defined as an imbalance between the load of proteins in the ER and the capacity of the organelle to handle these. When ER homeostasis is perturbed, signaling pathways are activated, leading to an adaptive response called the unfolded protein response (UPR). Three transmembrane proteins govern the UPR. Protein kinase-like ER kinase (PERK) attenuates protein translation, whereas activating transcription factor (ATF)-6 and inositol-requiring kinase-1 (IRE1) increase ER folding capacity by upregulating ER chaperones and the ERassociated protein degradation machinery. The transcriptional regulation by IRE1 is mediated by its downstream effectors X-box binding protein 1 (XBP1) and JNK. 13, 14 The prime function of the UPR is to restore ER homeostasis. The b-cells are particularly sensitive to disturbances in the ER because of the high demand for insulin production. 15 In vitro, saturated FFAs induce more pronounced proapoptotic ER stress signaling compared with unsaturated FFAs. 16, 17 Rats fed a high-fat diet have increased b-cell PERK phosphorylation and BiP expression.
The activating protein 1 (AP-1) transcription factor is formed by several protein families, including Jun (c-Jun, JunB and JunD), Fos (c-Fos, FosB, Fra1 and Fra2) and ATF (ATF2, ATF3, JDP1 and JDP2). AP-1 can be formed of homodimers or heterodimers; these combinatorial possibilities result in diverse outcomes in terms of gene regulation. JunB has been extensively studied in cancer models where it acts as a tumor suppressor. 19 In cellular models of type 1 diabetes (cytokinetreated b-cells), JunB was shown to promote b-cell survival by inhibiting NF-kB activity 20 and regulating ATF3 expression. 21 GLP-1 agonists such as exendin-4, used for the treatment of T2D, have been shown to improve insulin secretion and preserve b-cell mass. Part of their protective effect is mediated by upregulation of JunB expression 22 and consequent protection against FFA-induced b-cell apoptosis.
The mechanism(s) by which JunB protects b-cells from lipotoxicity is unknown. In this study we interrogated the molecular pathways involved in JunB-mediated b-cell protection against palmitate. By array analysis and a series of focused experiments we found that JunB modulates the ER stress response and AKT signaling. JunB-dependent induction of XBP1 mediates the crosstalk between these pathways, constituting a crucial defense mechanism against lipotoxic b-cell death.
Results
JunB modulates lipotoxic b-cell death. Palmitate induced JunB mRNA expression from 8 to 24 h of exposure (Figure 1a) . At the protein level, JunB was initially upregulated by palmitate (2 to 8 h) but its expression decreased at later time points (16 to 24 h, Figure 1a ), when cell death becomes apparent. JNK has been shown to phosphorylate JunB, leading to its proteasomal degradation. 23 JNK inhibition using the chemical JNK inhibitor SP600125 prevented the downregulation of JunB by palmitate (Figure 1b) , demonstrating that palmitate-induced JNK activation leads to JunB degradation. We have previously shown that JunB knockdown (KD) potentiates palmitate-induced apoptosis in INS-1E cells. 22 We confirmed these results here ( Figure 1c ) and showed increased caspase 3 activation after JunB KD in palmitate-treated INS-1E cells (Figure 1d ). JunB deficiency also sensitized primary rat b-cells (Figure 1e ) and dispersed human islet cells to lipotoxicity (Figure 1f Table S1 ). In JunB KD cells treated for 14 h with palmitate, we observed decreased expression of antiapoptotic and ER stress response genes, whereas genes related to regulation of transcription and dephosphorylation, including the AKT inhibitor PTEN, were upregulated (Supplementary Table S1 ). IPA of this data set showed that cell cycle, RhoGDI signaling and PI3K/AKT signaling were the top canonical pathways modified by JunB KD. In agreement with the changes in the ER stress response pathway, there was an enrichment (P ¼ 2.8E À 05) of genes previously shown to be upregulated by XBP1s (Supplementary Table S2 ). From the 13 XBP1-dependent genes, 12 were downregulated in JunB-deficient cells, pointing to a possible link between JunB and XBP1. Genes were also classified by a previously described manual curation 24 according to their potential role in b-cell dysfunction and death ( Figure 2 and Supplementary Table S1 ). Genes involved in insulin secretion, such as SNAP25 and synaptotagmin IV, 25 were inhibited by JunB depletion in palmitate-treated b-cells (Figure 2 and Supplementary Table  S1 ). There was no change in glucose-stimulated insulin secretion (GSIS) in JunB-depleted cells exposed to palmitate for 16 h (data not shown). We also analyzed GSIS in INS-1E cells exposed for 48 h to a lower, nontoxic (0.4 mM) concentration of palmitate (Supplementary Figure S2A) . Palmitate inhibited both insulin content and GSIS (Supplementary Figures S2B and C) . JunB KD did not alter basal or GSIS or insulin content (Supplementary Figures S2B and C) in control or palmitate-treated cells. JunB KD did not alter the proinsulin/insulin ratio in the culture medium (data not shown). These analyses suggest that JunB mostly modulates gene networks involved in the regulation of apoptosis and the ER stress response, and thereby promotes b-cell homeostasis.
Role of JunB in the ER stress response. Based on the array analyses we investigated the role of JunB in the ER stress response in b-cells. For this purpose we silenced or overexpressed JunB and evaluated signaling in the three main branches of the UPR, controlled by IRE1, PERK and ATF6. In keeping with the array data, JunB-deficient cells expressed less total and spliced XBP1 mRNA and XBP1 protein (Figures 3a and b) . JunB overexpression increased both forms of XBP1 (Figures 3c and d) . The changes in XBP1 expression were independent of IRE1 activity, as JunB siRNA or adenovirus did not alter IRE1 phosphorylation levels (Figures 3a and c Figure S4G ), arguing for a specific role of JunB in the modulation of the ER stress response.
As XBP1s has a very short half-life, 13 changes in protein stability may influence its steady-state expression levels. We tested whether JunB modulates XBP1 stability by overexpressing XBP1s in JunB-depleted cells treated with the protein synthesis inhibitor cycloheximide. The decay of XBP1s was not altered by JunB silencing (Figure 4a ), suggesting that JunB upregulates XBP1s through transcriptional activation. As IRE1 signaling can be pro-or anti-apoptotic in a context-dependent manner, 26, 27 we investigated whether this pathway is involved in JunBmediated b-cell protection. For this purpose, we upregulated JunB expression using an adenoviral vector and silenced XBP1 ( JunB-driven XBP1 expression is c/EBPd dependent. As the maintenance of XBP1 expression by JunB is crucial for b-cell survival under lipotoxic conditions, we next investigated the molecular mechanisms involved. In silico analysis of the XBP1 promoter revealed the presence of a highly conserved c/EBP binding element at À 504 bp relative to the transcription start site. 29 From the c/EBP family of transcription factors, only the d-isoform was induced by palmitate in a JunB-dependent manner (Figure 2 and Supplementary Table S1 ). We confirmed these results, showing that palmitate induced c/EBPd mRNA and protein with a peak at 8 h (Figures 5a and b) . JunB KD abolished the c/EBPd upregulation (Figures 5c and d) . When c/EBPd was silenced (Figure 5e ), palmitate no longer upregulated total XBP1 mRNA (Figure 5f ) or XBP1 protein expression (Figure 5g ) and cell death was enhanced (Figure 5h) . Conversely, JunB overexpression induced c/EBPd in parallel with XBP1s (Figure 5i ). These results point to c/EBPd as an important mediator of XBP1 induction by JunB and an integral part of the b-cell-protective response in lipotoxicity.
JunB modulates AKT signaling. In our array analysis, PTEN, an inhibitor of AKT, was upregulated in palmitatetreated JunB-deficient cells (Figure 2 and Supplementary  Table S1 ). We therefore examined whether AKT signaling is inhibited following JunB silencing. PTEN phosphorylation or expression was not altered by palmitate (Supplementary Figure S7A) . Next, we confirmed that PTEN expression was induced by JunB KD in control and palmitate-treated cells (Figure 6a and Supplementary Figure S7B) . PTEN phosphorylation was also increased in JunB KD (Figure 6a and Supplementary Figure S7C ) cells but the ratio of p-PTEN/PTEN did not change (Supplementary Figure  S7D) , suggesting that JunB KD mainly affects total PTEN expression. Importantly, AKT phosphorylation was markedly reduced in JunB-deficient cells (Figure 6a ). Under normal conditions, AKT phosphorylates and thereby inhibits BAD, a proapoptotic BH3-only member of the Bcl-2 family. In palmitate-treated, JunB-deficient cells, BAD phosphorylation was decreased (Figure 6a ). The proapoptotic Bcl-2 family members DP5 and PUMA, previously shown to play a role in palmitate-induced apoptosis, 11 were not induced by JunB KD (PUMA was actually inhibited), and neither was the expression of the antiapoptotic Bcl-2 and Bcl-XL proteins modified (Supplementary Figures S7E-G) . To formally test the role of BAD in JunB-deficient lipotoxic b-cell death, we double knocked down JunB and BAD (Figure 6b ). BAD silencing fully protected against JunB KD-dependent apoptosis in palmitate-treated cells (Figure 6c) , identifying BAD as a key downstream effector.
As JunB KD decreased AKT phosphorylation, we tested whether JunB induction would potentiate AKT activation. Adenoviral JunB overexpression induced AKT phosphorylation in a dose-dependent manner, supporting the important role for JunB in AKT regulation (Figure 6d Figure S7A ) was prevented in cells overexpressing XBP1s (Figure 6f ), demonstrating the important role of XBP1s for AKT phosphorylation. As XBP1 KD per se did not alter PTEN protein expression, we examined alternative mechanisms. To test whether PTEN is responsible for the AKT inhibition in JunB-deficient cells we used the PTEN inhibitor Vo-OHPic. Interestingly, AKT inhibition was not reversed by the PTEN inhibitor (Figure 6g) . Similar results were obtained using two PTEN siRNAs (data not shown). Thus, the modulation of AKT activation by JunB is dependent on XBP1 but not PTEN. We next evaluated whether insulin could be the link between JunB-XBP1s and the activation of AKT. For this purpose, we inhibited insulin release using diazoxide 32 or we treated cells with a 10-fold excess concentration of insulin as compared with the cumulative insulin released to the medium after 16 h of culture. Diazoxide did not alter AKT phosphorylation in cells transfected with negative, JunB or XBP1 siRNAs (Supplementary Figure S8) . In insulin-treated cells, AKT phosphorylation remained inhibited by JunB or XBP1 KD (Supplementary Figures S8A and D) . These results are in agreement with the lack of modulation of insulin secretion by JunB (Supplementary Figure S2B) and suggest that JunB and XBP1 do not regulate AKT via modulation of insulin release.
AKT induction by JunB is essential for GLP-1 protection from lipotoxicity. We have previously shown that GLP-1 agonists, widely used to treat T2D, protect b-cells from palmitate via the induction of JunB. 22 We hypothesized that the JunB/XBP1/AKT axis would also operate in this context. To examine the role of AKT in GLP-1-mediated b-cell survival, we inhibited AKT using the PI3K inhibitor wortmannin (Figure 7a ). The GLP-1 agonist exendin-4 or the adenylate cyclase stimulator forskolin, a more potent intracellular cAMP inducer, failed to protect cells from palmitate when used in combination with wortmannin (Figure 7b) , showing that AKT is crucial for b-cell protection under lipotoxic conditions. In keeping with our previous results, 22 forskolin stimulated JunB expression and AKT phosphorylation (Figures 7a and c) . The latter was partially prevented by JunB KD (Figure 7c) .
To investigate the role of XBP1 in the induction of AKT by GLP-1/cAMP, we used the potent IRE1 inhibitor 4m8C that severely inhibits expression of XBP1s (Figure 7d and Supplementary Figure S9 ). This XBP1 depletion decreased AKT phosphorylation (Figure 7d) . Importantly, the protection against palmitate conferred by forskolin was lost in the absence of XBP1 (Figure 7e ). We confirmed that forskolininduced AKT phosphorylation was markedly decreased and its b-cell-protective effect reduced following XBP1 KD by siRNA (Figures 7f and g ). These results demonstrate that AKT activation by GLP-1 agonists is JunB/XBP1 dependent and essential for b-cell survival under lipotoxic conditions.
Discussion
Loss of functional b-cell mass contributes to the development of T2D. Most of the current treatments for T2D focus on lifestyle changes and the enhancement of insulin secretion. At later stages of the disease, these approaches tend to fail and patients need to be placed on insulin therapy. In this context, approaches to preserve or rescue b-cells are important to prevent or treat T2D. Here we show that the transcription factor JunB orchestrates an intricate crosstalk between the UPR and AKT signaling that protects b-cells from lipotoxicity ( Figure 8) .
The early induction of JunB by palmitate constitutes an important antiapoptotic mechanism operating in rat and Our global analysis of gene expression in JunB-deficient cells pointed to the ER stress response and AKT signaling as possible mechanisms for the JunB-mediated b-cell protection. Indeed, JunB deficiency decreases XBP1 expression, a transcription factor induced by the IRE1-mediated unconventional alternative splicing of its mRNA during ER stress. XBP1s induces ER chaperones and components of the ER-associated protein degradation machinery, improving ER folding capacity and degrading malfolded proteins, essential adaptation steps for cell survival under stress conditions (see Lee et al. 34 and present data). Unspliced XBP1 is constitutively expressed and further induced during ER stress by XBP1s and ATF6. 35, 36 Our results show a novel pathway in which XBP1 expression is regulated by JunB via the transcription factor c/EBPd. We cannot exclude that JunB regulates XBP1 directly, but in silico analysis of the rat XBP1 promoter did not identify AP-1-binding sites. In addition, c/EBPd KD reproduces the phenotype of JunB-deficient cells, arguing for the indirect scenario. In adipocytes, XBP1 was shown to be modulated by c/EBPb to induce adipogenesis. 37 Induction of XBP1 is crucial for the JunB-mediated defense mechanism against palmitate as XBP1 KD in JunB-overexpressing cells abrogates the JunB protection. In an earlier study, we did not find evidence for a role of XBP1 in GLP-1 protection from lipotoxicity. 22 This may have been because of the inefficient KD (51 ± 14%) in the previous study compared with the new data presented here (74 ± 4%). We show here that JunB-mediated XBP1 expression protects cells from lipotoxicity through the induction of AKT. In JunB-or XBP1-deficient cells AKT phosphorylation is downregulated whereas JunB overexpression stimulates its phosphorylation. To our knowledge, this is the first time that an AP-1 family member is shown to interact with the ER stress response to promote antiapoptotic signaling. AKT activation is a critical prosurvival signal in b-cells by inhibiting FOXO transcription factors, BAD and GSK3b via direct phosphorylation. AKT signaling has been shown to protect b-cells from FFA-or ER stress-induced apoptosis 38, 39 and to mediate part of the antiapoptotic effects of GLP-1 agonists. 22 This important prosurvival role of AKT is demonstrated here by the increased apoptosis observed in palmitate-treated cells when JunB or XBP1 were knocked down or AKT was inhibited by wortmannin. The reduction of AKT phosphorylation observed under these conditions leads to BAD dephosphorylation and consequent activation of apoptosis. This conclusion is supported by the observation that BAD KD reverts the increased apoptosis observed in JunB-deficient cells treated with palmitate.
PTEN, an inhibitor of PI3K, was upregulated in the absence of JunB in b-cells in the array analysis and western blot. Deletion of PTEN in muscle improves insulin sensitivity in T2D models. 40 In addition, specific PTEN KO in b-cells increased b-cell mass and protected from diabetes induced by high-fat diet. 41 These effects were attributed to increased AKT activity. The decreased AKT phosphorylation in JunB KD b-cells, however, is not mediated by PTEN as its KD or chemical inhibition does not alter AKT phosphorylation. In support of this conclusion, XBP1-deficient cells have reduced AKT phosphorylation without changes in PTEN expression compared with JunB KD cells. XBP1 has been shown to modulate AKT activity in other cell types, 31, 42 and XBP1 may directly bind PI3K, facilitating AKT phosphorylation in endothelial cells. 43 JunB may also modulate AKT phosphorylation through a XBP1-dependent improvement of the ER folding capacity and consequent restoration of mTOR or via inhibition of protein phosphatase 2A, two important pathways previously shown to regulate AKT. [44] [45] [46] Incretin analogs such as exendin-4 are used for the treatment of T2D. Exendin-4 binds to the GLP-1 receptor, increasing cAMP production and thereby stimulating the activation of several signaling pathways such as PKA, mTOR and AKT. Activation of these pathways potentiates GSIS, increases b-cell mass in rodents and protects from oxidative stress and proinflammatory cytokines. 47, 48 The role of AKT in GLP-1-mediated b-cell survival under lipotoxic conditions has previously been demonstrated, 49 but the mechanisms by which GLP-1-induced cAMP activates AKT are not well established. The present study provides evidence that induction of the JunB-XBP1 axis contributes to increase AKT phosphorylation by exendin-4 and forskolin and protect from lipotoxicity. These novel insights connect the AP-1 and the ER stress response in a complex chain of events that stimulates AKT activation.
In conclusion, we show that JunB is a crucial prosurvival transcription factor for b-cells. JunB promotes XBP1 signaling and AKT activation, thereby preventing b-cell apoptosis. In addition, the JunB-XBP1 pathway contributes to activate AKT signaling by GLP-1 agonists. The crosstalk between these pathways constitutes a crucial defense mechanism against lipotoxic b-cell death and may represent an important mechanism for the prevention/treatment of T2D.
Materials and Methods
Culture of INS-1E, FACS-purified primary rat b-cells and human islet cells. Male Wistar rats (Charles River Laboratories, Brussels, Belgium) were used according to the guidelines of the Belgian Regulations for Animal Care. All experiments were approved by the local Ethical Committee. Islets were separated by collagenase digestion, handpicked and dispersed in single cells. b-Cells were purified by autofluorescence-activated cell sorting (FACSAria, BD Bioscience, San Jose, CA, USA), 50 yielding a purity of 93 ± 1% (n ¼ 4). b-Cells were cultured for 2 days in Ham's F-10 medium containing 10 mM glucose and 5% heat-inactivated fetal bovine serum (FBS) before further experiments. The rat insulin-producing INS-1E cell line (a kind gift from Professor C Wollheim, Centre Medical Universitaire, Geneva, Switzerland) was cultured in RPMI-1640 (with 2 mM GlutaMAX-I) containing 5% FBS 51 and used at passages 59-73. Human islets (from 9 donors, age 62±5 years, BMI 25±3 kg/m 2 , 6 male and 3 female, cause of death was cerebral hemorrhage (4), cardiovascular disease (3), trauma (1) or unknown (1)) were isolated by collagenase digestion and density gradient purification. 52 The islets were cultured, dispersed and transfected as described previously. 53 The percentage of b-cells, examined by insulin immunofluorescence, 17 was 53 ± 7%.
Treatments. For FFA exposure, primary b-cells were cultured in medium with 1% BSA without FBS and INS-1E cells in medium with 1% FBS and 1% BSA. 54 Palmitate (Sigma, Schnelldorf, Germany) was dissolved in 90% ethanol, 17 and used at a final concentration of 0.5 mM in the presence of 1% BSA, resulting in unbound FFA concentrations in the nM range. 54 The JNK inhibitor SP600125 (Sigma) was used at 10 mM for 2 h before and during FFA exposure. 17 PTEN inhibitor Vo-OHpic (Sigma) was used at 0.5 mM for 2 h before and during FFA exposure. The IRE1 inhibitor 4m8C 55 was used at 25 mM during FFA exposure. Exendin-4 was diluted in RPMI-1640 and used at 50 nM. Insulin was used at 26 mg/ml (Actrapid, Novo Nordisk, Bagsvaerd, Denmark). Forskolin, cycloheximide, diazoxide and the PI3K inhibitor wortmannin (Sigma) were diluted in DMSO and used at concentrations of 20 mM, 5 mg/ml, 100 mM and 100 nM, respectively. At the concentration used, diazoxide inhibits insulin secretion by 480%.
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RNAi. Proteins were knocked down using previously validated 11, 20, 22, 56 specific siRNAs against JunB, XBP1, c/EBPd and BAD (all from Invitrogen, Carlsbad, CA, USA) and PERK (SMARTpool, Dharmacon, Chicago, IL, USA), or a negative control of 21 nucleotide duplex RNA (Qiagen, Hilden, Germany) that does not affect b-cell function, gene expression or viability. 57 Lipid-RNA complexes were formed in Opti-MEM (1 ml Lipofectamine RNAiMAX, Invitrogen, to 150 nM siRNA) and added at a final concentration of 30 nM siRNA. 17 Transfected cells were cultured for 2 to 3 days before treatment.
Microarray analysis. INS-1E cells were transfected with JunB or a negative control siRNA. Two days later, cells were treated or not for 6 or 14 h with 0.5 mM palmitate. RNA was isolated using the RNeasy Mini Kit (Qiagen) and prepared for hybridization as previously described. 24 The array was performed in three independent experiments using the GeneChip Rat Genome 230 2.0 arrays (Affymetrix, Santa Clara, CA, USA) containing 431 000 probe sets covering 28 000 rat genes as previously described. 11 Data analysis was performed using the DAVID and IPA 5.5 software. The complete array data will be deposited after publication of this article in the Eurodia database (http://eurodia.vital-it.ch).
Real-time PCR. Poly(A) þ -RNA was isolated and reverse transcribed as described previously. 58 The real-time PCR amplification was done using IQ SYBR Green Supermix (BIO-RAD, Hercules, CA, USA) on a MyiQ2 instrument and the PCR product concentration calculated as copies/ml using a standard curve. 59 Gene expression was corrected for the expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and normalized to the highest expression value within an experiment. b-Actin was used as the housekeeping gene for human islets. 17 The primer sequences were: for rat total XBP1 forward 5 0 -GAGCAGCAAGTGGTGGATTT-3 0 and reverse 5 0 -TCTCAATCA CAAGCCCATGA-3 0 , for rat GRP94 forward 5 0 -AAGGTCATTGTCACGTCGAAA-3 0 and reverse 5 0 -GTGTTTCCTCTTGGGTCAGC-3 0 . The other primer sequences have been reported elsewhere. 21, 22, 60 Western blot. Western blots were performed using 20 mg whole-cell extract protein as described. 60 IRE1 phosphorylation was detected using Phos-tag-SDS gels. Briefly, cell lysates were run on SDS-PAGE with 10 mM Phos-tag reagent (Wako, Richmond, VA, USA) and 10 mM MnCl 2 . Gels were then washed for 30 min in transfer buffer containing 1 mM EDTA and proteins transferred to a nitrocellulose membrane. The primary antibodies were anti-p-eIF2a (Ser51), b-actin, Bcl-2, Bcl-XL, p-c-Jun (Ser73), p-JNK (Thr183, Tyr185), PERK, p-PERK (Thr980), IRE1, p-AKT (Ser473), AKT, p-PTEN (Ser380, Thr382/383), PTEN, BiP, p-BAD (Ser112), BAD and cleaved caspase 3 from Cell Signaling (Beverly, MA, USA), JunB, c/EBPd, XBP1, ATF3 and CHOP from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and anti-a-tubulin (1 : 10 000) from Sigma. For XBP1, the bands correspond to the 54 kDa spliced form of XBP1. Horseradish peroxidaselabeled donkey anti-rabbit or donkey anti-mouse (1 : 10 000, Jackson Immuno Research, Baltimore Pike, PA, USA) antibodies were used as secondary antibodies. Protein signal was visualized using chemiluminescence Supersignal (Pierce, Rockford, IL, USA) and quantified using Scion Image (Scion Corporation, Frederick, MD, USA).
Protein biosynthesis. Protein synthesis was measured as previously reported. 60 Briefly, INS-1E cells were cultured for 2 h in Krebs-Ringer buffer containing 1% BSA, 11 mM glucose and 10 mCi/ml L-(4,5-3H)-leucine (NET135H; PerkinElmer Life Sciences, Waltham, MA, USA) with or without palmitate. The content of 3H-labeled protein was determined by measuring the radioactivity using a liquid scintillation analyzer (Packard, Meriden, CT, USA). Protein biosynthesis was expressed per total protein content.
Infection with recombinant adenoviruses. Cells were infected either with AdLUC (a luciferase expressing control virus), AdJunB (expressing the rat JunB protein, purchased from RIKEN BioResource Center, Tsukuba, Japan) or AdXBP1 (expressing mouse XBP1s 27 ) and used at the indicated multiplicity of infection. After 3 h of infection, the medium was changed.
Assessment of b-cell apoptosis. Apoptotic b-cells and INS-1E cells were counted in fluorescence microscopy after staining with the DNA-binding dyes propidium iodide (5 mg/ml) and Hoechst 33342 (10 mg/ml). 60 Apoptosis was confirmed by western blot analysis of cleaved caspase 3.
Glucose-stimulated insulin secretion. INS-1E cells were cultured for 1 h with RPMI-1640 without glucose supplemented with 5% FBS. Cells were then incubated for 30 min in modified Krebs-Ringer bicarbonate HEPES solution 11 without glucose. Insulin secretion was induced by 30 min of incubation with KRBH containing 1.7 or 16.7 mM glucose. Insulin or proinsulin was measured by ELISA in cell-free supernatants and acid-ethanol extracted cell lysates (Mercodia, Uppsala, Sweden).
Statistical analysis. Data are presented as means ± S.E. of the indicated number (n) of independent experiments. Comparisons were performed by ANOVA followed by paired t-test with the Bonferroni correction for multiple comparisons. A P-value of o0.05 was considered statistically significant. 
